Life Sciences Innovator Poised for 35% Upside
Positioned at the heart of genomics and diagnostics, this mid-cap player combines recurring revenues with strategic buybacks, offering attractive upside with limited downside risk.
Positioned at the heart of genomics and diagnostics, this mid-cap player combines recurring revenues with strategic buybacks, offering attractive upside with limited downside risk.
